BioStock: Cereno comments on EU orphan designation for CS1

Cereno Scientific has received Orphan Medicinal Product Designation in the EU for CS1 in Pulmonary Arterial Hypertension, a rare cardiovascular disease. The decision comes as the company awaits topline data from a phase II trial evaluating CS1 in PAH. BioStock spoke with Cereno’s CEO Sten R. Sörensen to get his take on why this is a key milestone for the company.

Read the interview with CEO Sten R. Sörensen at biostock.se:

https://www.biostock.se/en/2024/09/cereno-comments-on-eu-orphan-designation-for-cs1/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/en/